These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 31570182)

  • 1. Health impact and cost-effectiveness of introducing the vaccine (Bexsero) against MenB disease into the Brazilian immunization programme.
    Moura Silveira M; McBride AJA; Trotter CL
    Vaccine; 2019 Oct; 37(45):6783-6786. PubMed ID: 31570182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiological impact and cost-effectiveness of universal vaccination with Bexsero(®) to reduce meningococcal group B disease in Germany.
    Christensen H; Irving T; Koch J; Trotter CL; Ultsch B; Weidemann F; Wichmann O; Hellenbrand W
    Vaccine; 2016 Jun; 34(29):3412-9. PubMed ID: 27109566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of vaccination against meningococcal B among Dutch infants: Crucial impact of changes in incidence.
    Pouwels KB; Hak E; van der Ende A; Christensen H; van den Dobbelsteen GP; Postma MJ
    Hum Vaccin Immunother; 2013 May; 9(5):1129-38. PubMed ID: 23406816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health and economic outcomes of introducing the new MenB vaccine (Bexsero) into the Italian routine infant immunisation programme.
    Tirani M; Meregaglia M; Melegaro A
    PLoS One; 2015; 10(4):e0123383. PubMed ID: 25874805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France.
    Lecocq H; Parent du Châtelet I; Taha MK; Lévy-Bruhl D; Dervaux B
    Vaccine; 2016 Apr; 34(19):2240-50. PubMed ID: 27002504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada.
    Tu HA; Deeks SL; Morris SK; Strifler L; Crowcroft N; Jamieson FB; Kwong JC; Coyte PC; Krahn M; Sander B
    Vaccine; 2014 Sep; 32(42):5436-46. PubMed ID: 25131732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: A cost-effectiveness analysis.
    Gasparini R; Landa P; Amicizia D; Icardi G; Ricciardi W; de Waure C; Tanfani E; Bonanni P; Lucioni C; Testi A; Panatto D
    Hum Vaccin Immunother; 2016 Aug; 12(8):2148-2161. PubMed ID: 27163398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of 4CMenB Infant Vaccination in England: A Comprehensive Valuation Considering the Broad Impact of Serogroup B Invasive Meningococcal Disease.
    Beck E; Klint J; Neine M; Garcia S; Meszaros K
    Value Health; 2021 Jan; 24(1):91-104. PubMed ID: 33431159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience with the meningococcal B vaccine, Bexsero(®): Prospects for reducing the burden of meningococcal serogroup B disease.
    Watson PS; Turner DP
    Vaccine; 2016 Feb; 34(7):875-80. PubMed ID: 26686570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B
    Mulhall RM; Bennett D; Cunney R; Borrow R; Lucidarme J; Findlow J; Jolley KA; Bray J; Maiden MCJ; Moschioni M; Serino L; Stella M; Medini D
    mSphere; 2018 Aug; 3(4):. PubMed ID: 30135218
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-Effectiveness of Meningococcal Vaccination Among Men Who Have Sex With Men in New York City.
    Simon MS; Weiss D; Geevarughese A; Kratz MM; Cutler B; Gulick RM; Zucker JR; Varma JK; Schackman BR
    J Acquir Immune Defic Syndr; 2016 Feb; 71(2):146-54. PubMed ID: 26334735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales.
    Trotter CL; Edmunds WJ
    BMJ; 2002 Apr; 324(7341):809. PubMed ID: 11934772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of a universal infant immunization program with meningococcal C conjugate vaccine in Brazil.
    de Soarez PC; Sartori AM; de Andrade Lagoa Nóbrega L; Itria A; Novaes HM
    Value Health; 2011 Dec; 14(8):1019-27. PubMed ID: 22152170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study.
    Parikh SR; Andrews NJ; Beebeejaun K; Campbell H; Ribeiro S; Ward C; White JM; Borrow R; Ramsay ME; Ladhani SN
    Lancet; 2016 Dec; 388(10061):2775-2782. PubMed ID: 28100432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The introduction of the meningococcal B (MenB) vaccine (Bexsero®) into the national infant immunisation programme--New challenges for public health.
    Ladhani SN; Campbell H; Parikh SR; Saliba V; Borrow R; Ramsay M
    J Infect; 2015 Dec; 71(6):611-4. PubMed ID: 26433141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of alternative strategies for vaccination of adolescents against serogroup B IMD with the MenB-FHbp vaccine in Canada.
    Breton MC; Huang L; Snedecor SJ; Cornelio N; Fanton-Aita F
    Can J Public Health; 2020 Apr; 111(2):182-192. PubMed ID: 31907760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands.
    Bos JM; Rümke HC; Welte R; Spanjaard L; van Alphen L; Postma MJ
    Pharmacoeconomics; 2006; 24(2):141-53. PubMed ID: 16460135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluation of meningococcal serogroup B (MenB) vaccines: A systematic review.
    Nwogu IB; Jones M; Langley T
    Vaccine; 2021 Apr; 39(16):2201-2213. PubMed ID: 33744052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modelling the cost-effectiveness of catch-up 'MenB' (Bexsero) vaccination in England.
    Christensen H; Trotter CL
    Vaccine; 2017 Jan; 35(2):208-211. PubMed ID: 27923519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact.
    Christensen H; Hickman M; Edmunds WJ; Trotter CL
    Vaccine; 2013 May; 31(23):2638-46. PubMed ID: 23566946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.